Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2008 by University Hospital Birmingham.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University Hospital Birmingham
ClinicalTrials.gov Identifier:
NCT00698074
First received: June 11, 2008
Last updated: June 13, 2008
Last verified: June 2008
  Purpose

The primary aim of this study will be to assess whether Biventricular pacing improves exercise capacity, and Quality of Life in patients with symptomatic drug resistant Non-Obstructive Hypertrophic Cardiomyopathy, using a Biventricular pacemaker.


Condition Intervention Phase
Hypertrophic Cardiomyopathy
Device: Cardiac Resynchronisation Therapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy

Resource links provided by NLM:


Further study details as provided by University Hospital Birmingham:

Estimated Enrollment: 32
Arms Assigned Interventions
Experimental: 1
Cardiac Resynchronisation Therapy
Device: Cardiac Resynchronisation Therapy
Biventricular Pacemaker Implant

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Symptomatic Hypertrophic Cardiomyopathy,

Exclusion Criteria:

  • Rhythm other than normal sinus Left ventricular outflow tract gradient greater than 30mmHg Inability to exercise v02 max greater than 70% of predicted.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00698074

Contacts
Contact: Michael P Frenneaux, MBBS 121-414-5916 ext 5916 m.p.frenneaux@bham.ac.uk

Locations
United Kingdom
Department Cardiovascular Medicine, University of Birmingham Recruiting
Birmingham, West Midlands, United Kingdom, B15 2TT
Contact: ibrar ahmed, MBChB    121-414-5916    01ahmedi@gmail.com   
Sponsors and Collaborators
University Hospital Birmingham
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00698074     History of Changes
Other Study ID Numbers: 05/Q2709/64
Study First Received: June 11, 2008
Last Updated: June 13, 2008
Health Authority: United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Cardiomyopathies
Cardiomyopathy, Hypertrophic
Hypertrophy
Aortic Stenosis, Subvalvular
Aortic Valve Stenosis
Cardiovascular Diseases
Heart Diseases
Heart Valve Diseases
Pathological Conditions, Anatomical

ClinicalTrials.gov processed this record on November 20, 2014